NCT06617455View on ClinicalTrials.gov

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

October 1, 2026

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Breast Ductal Carcinoma In SituLocalized Breast Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Fezolinetant

Given PO

DRUG

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

48109

RECRUITING

University of Michigan Rogel Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

The Breast Cancer Research Foundation

UNKNOWN

lead

University of Michigan Rogel Cancer Center

OTHER